These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23235972)

  • 61. Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer.
    Sundaresan L; Kumar P; Chatterjee S
    Future Oncol; 2018 Oct; 14(23):2383-2401. PubMed ID: 30141351
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer.
    Wilding G; Grindey G; Munshi N; Seitz D; Einhorn L
    Invest New Drugs; 1993; 11(2-3):203-5. PubMed ID: 8262732
    [No Abstract]   [Full Text] [Related]  

  • 63. Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
    Citrin DL; Elson P; DeWys WD
    Cancer; 1984 Jul; 54(1):13-7. PubMed ID: 6372984
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hormone therapy in prostate cancer.
    Currie GM; Haase M; Hashmi R; Kiat H
    J Nucl Med Technol; 2013 Mar; 41(1):49-51. PubMed ID: 23404051
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Disseminated intravascular coagulation during treatment with thalidomide. A case report.
    Tassinari D; Tombesi P; Sartori S
    Tumori; 2008; 94(5):746-7. PubMed ID: 19112952
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Survival from lung cancer not improved with thalidomide.
    Nurs Stand; 2009 Sep; 24(1):18-19. PubMed ID: 28090924
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.
    Hiramatsu T; Yoshizawa J; Miyaguni K; Sugihara T; Harada A; Kaji S; Uchida G; Kanamori D; Baba Y; Ashizuka S; Ohki T
    Pediatr Surg Int; 2018 Apr; 34(4):443-450. PubMed ID: 29423589
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vascular endothelial growth receptor 1 acts as a stress-associated protein in the therapeutic response to thalidomide.
    Liu Q; Yin T; Wang G; Guo F; Ou Y; Li Y; Wang Y
    Exp Ther Med; 2017 Nov; 14(5):4263-4271. PubMed ID: 29075340
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines
    Qiao Z; Yuan J; Shen J; Wang C; He Z; Hu Y; Zhang M; Xu C
    Oncol Lett; 2015 May; 9(5):2353-2360. PubMed ID: 26137070
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting metastatic prostate cancer: the search for innovative systemic therapies.
    Berthold DR; Moore MJ
    Oncology (Williston Park); 2006 Dec; 20(14):1787-91; discussion 1791-6. PubMed ID: 17263128
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Challenges and recommendations for early identification of metastatic disease in prostate cancer.
    Crawford ED; Stone NN; Yu EY; Koo PJ; Freedland SJ; Slovin SF; Gomella LG; Berger ER; Keane TE; Sieber P; Shore ND; Petrylak DP;
    Urology; 2014 Mar; 83(3):664-9. PubMed ID: 24411213
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
    Rezvani H; Haghighi S; Ghadyani M; Attarian H
    Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
    Rexer H
    Urologe A; 2011 Jun; 50(6):722-4. PubMed ID: 21584827
    [No Abstract]   [Full Text] [Related]  

  • 75. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.